As alluded to earlier, RAS blockade exists in virtually all SGLT2 inhibitor trials in CKD patients, suggesting separate mechanisms and an additive benefit with these two critical treatments of CKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.